Health Tech Capitol | FDA approves Madison-based skin graft technology to treat burns
17071
post-template-default,single,single-post,postid-17071,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

FDA approves Madison-based skin graft technology to treat burns

16 Jun FDA approves Madison-based skin graft technology to treat burns

Posted at 10:46h in Uncategorized by
0 Likes

The U.S. Food and Drug Administration on Tuesday approved StrataGraft, a topical treatment for severe burns made from skin tissue, providing a boost for Madison-based firm Stratatech.

The FDA approval is supported by two clinical studies involving a total of 101 adult patients. The StrataGraft treatment demonstrated effectiveness in eliminating the need for donor tissue harvest and achieved a complete wound closure in a majority of patients. There were no reports of rejection. 

Steven Romano, the executive vice president and chief scientific officer at Statatech’s owner Mallinckrodt Pharmaceuticals, called the FDA’s decision a “significant milestone” in the burn care community.

Read more at the Cap Times

No Comments

Sorry, the comment form is closed at this time.